What is the recommended dosing regimen of Welchol (colesevelam) for bile‑acid sequestration to lower LDL‑cholesterol?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Welchol (Colesevelam) Dosing for Bile Acid Sequestration

The recommended dose of Welchol (colesevelam) for bile acid sequestration to lower LDL-cholesterol is 3.75 grams daily, administered either as 6 tablets (625 mg each) taken once daily or 3 tablets taken twice daily with meals. 1, 2, 3

Standard Dosing Regimens

Tablet Formulation

  • 6 tablets (625 mg each) once daily with a meal, OR 1, 2, 3
  • 3 tablets twice daily with meals 1, 2, 3
  • Total daily dose: 3.75 grams 1, 2, 3

Oral Suspension Formulation

  • One 3.75-gram packet once daily mixed with 4-8 ounces of water, fruit juice, or diet soft drink, taken with a meal, OR 1, 2, 3
  • One 1.875-gram packet twice daily (mixed similarly) 1, 2
  • The 3.75-gram packet is equivalent to 6 tablets 3

Expected LDL-Cholesterol Reduction

Monotherapy

  • Colesevelam 3.75 grams daily reduces LDL-C by approximately 15-20% as monotherapy 1, 4, 5, 6
  • Some studies report reductions up to 18-25% at maximum doses 1

Combination Therapy with Statins

  • When added to low- to moderate-intensity statins, colesevelam provides an additional 10-16% reduction in LDL-C beyond statin monotherapy 1, 2
  • Combination therapy with atorvastatin 10 mg or simvastatin 10 mg showed additional reductions of 10-16% 1
  • In severe hypercholesterolemia with maximal statin and ezetimibe, colesevelam 3.75 g daily added an additional 18.5% LDL-C reduction over 12 weeks 1

Critical Administration Requirements

Must Take With Food

  • Colesevelam MUST be taken with meals 1, 2, 3
  • This is essential because colesevelam binds bile acids released during digestion 2
  • Taking with food ensures optimal interaction with bile acids and maximizes lipid-lowering effect 2

Drug Interaction Timing (Critical)

  • All other medications must be taken at least 4 hours BEFORE or 1 hour AFTER colesevelam 1, 2, 3
  • This is particularly critical for drugs with narrow therapeutic windows: 1, 2, 3
    • Thyroid hormone replacement
    • Warfarin
    • Phenytoin
    • Oral contraceptives (ethinyl estradiol/norethindrone)
    • Cyclosporine
    • Sulfonylureas (glimepiride, glipizide, glyburide)
    • Olmesartan medoxomil

Practical Scheduling

  • Schedule colesevelam with breakfast and/or dinner 2
  • Take other medications either first thing in the morning (1+ hours before colesevelam) or at bedtime (4+ hours after colesevelam) 2
  • Fat-soluble vitamins should be taken at least 4 hours before colesevelam 3

Dose Titration Considerations

No Titration Required for Cholesterol Lowering

  • Unlike cholestyramine and colestipol, colesevelam does NOT require dose titration 1
  • The standard 3.75 g/day dose can be initiated immediately 1, 3
  • This differs from cholestyramine (started at 4 g/day, titrated to maximum 24 g/day) and colestipol (started at 2-5 g/day) 1

For Bile Acid Diarrhea (Off-Label)

  • For bile acid diarrhea, colesevelam is typically dosed as 2 tablets (625 mg) three times daily with meals 1, 2
  • This totals 3.75 grams daily but divided into three doses 1
  • Gradual titration may be considered to minimize side effects in this indication 1

Special Populations

Pediatric Dosing (Ages 10-17)

  • For boys and postmenarchal girls aged 10-17 years with heterozygous familial hypercholesterolemia: 3.75 grams daily 1, 3
  • Same dosing regimen as adults (6 tablets once daily or 3 tablets twice daily with meals) 1, 3
  • Indicated when LDL-C remains ≥190 mg/dL after diet trial, or ≥160 mg/dL with family history of premature CVD or ≥2 CVD risk factors 1, 3

Type 2 Diabetes

  • Colesevelam 3.75 grams daily also improves glycemic control in type 2 diabetes, reducing HbA1c by approximately 0.5% 1, 2, 7
  • This provides dual benefit in diabetic patients with hypercholesterolemia 1, 2

Safety Profile and Adverse Effects

Common Side Effects

  • Most common adverse effects are gastrointestinal: constipation, dyspepsia, and nausea 1, 2, 3
  • These occur at rates similar to placebo (approximately 40%) 1, 2
  • Colesevelam has significantly better tolerability than traditional bile acid sequestrants like cholestyramine 1, 2

Contraindications

  • Contraindicated in patients with serum triglycerides >500 mg/dL 3
  • Contraindicated in patients with history of hypertriglyceridemia-induced pancreatitis 3
  • Contraindicated in patients with history of bowel obstruction 3

Monitoring Requirements

  • Obtain baseline lipid panel including triglycerides before starting colesevelam 1, 3
  • Monitor triglyceride levels periodically during therapy, as colesevelam may increase triglycerides 1, 2, 3
  • Monitor for signs of vitamin K or fat-soluble vitamin deficiencies in susceptible patients 3

Common Pitfalls to Avoid

Drug Interaction Errors

  • Failure to separate colesevelam from other medications by 4 hours is the most common error 1, 2, 3
  • This can lead to reduced efficacy of thyroid replacement, warfarin, oral contraceptives, and other critical medications 1, 2, 3

Not Taking With Food

  • Taking colesevelam without food significantly reduces its efficacy 2
  • The drug requires bile acids released during digestion to work properly 2

Use in High Triglycerides

  • Do not use colesevelam in patients with triglycerides >500 mg/dL 3
  • Colesevelam can increase triglycerides, potentially causing pancreatitis in susceptible patients 1, 3

Phenylketonuria Warning

  • The oral suspension contains 33.6 mg phenylalanine per 3.75-gram packet 3
  • This can be harmful to patients with phenylketonuria 3

Cardiovascular Outcomes Evidence

  • Bile acid sequestrants as a class have cardiovascular outcomes evidence from the LRC-CPPT trial with cholestyramine, showing reduced CHD events proportional to LDL-C lowering 1
  • While colesevelam specifically lacks dedicated cardiovascular outcomes trials, its LDL-C lowering effect is consistent with expected cardiovascular benefit based on Mendelian randomization analysis 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Colesevelam Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Colesevelam hydrochloride.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2002

Research

Colesevelam hydrochloride: a novel bile acid-binding resin.

The Annals of pharmacotherapy, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.